Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. lifted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 93.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,337 shares of the biotechnology company’s stock after purchasing an additional 18,005 shares during the period. Vontobel Holding Ltd.’s holdings in Biogen were worth $9,662,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in BIIB. Snowden Capital Advisors LLC grew its stake in shares of Biogen by 2.5% during the second quarter. Snowden Capital Advisors LLC now owns 1,591 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 39 shares in the last quarter. First Manhattan Co. grew its stake in shares of Biogen by 33.3% during the fourth quarter. First Manhattan Co. now owns 160 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 40 shares in the last quarter. Systematic Financial Management LP grew its stake in shares of Biogen by 2.5% during the first quarter. Systematic Financial Management LP now owns 1,640 shares of the biotechnology company’s stock worth $456,000 after purchasing an additional 40 shares in the last quarter. Stratos Wealth Partners LTD. boosted its stake in Biogen by 1.1% in the third quarter. Stratos Wealth Partners LTD. now owns 4,032 shares of the biotechnology company’s stock valued at $1,036,000 after acquiring an additional 42 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its stake in Biogen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 2,043 shares of the biotechnology company’s stock valued at $525,000 after acquiring an additional 45 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BIIB has been the subject of several research analyst reports. Piper Sandler decreased their price objective on shares of Biogen from $350.00 to $325.00 and set an “overweight” rating for the company in a research note on Wednesday, February 14th. Wedbush upped their price objective on shares of Biogen from $239.00 to $245.00 and gave the company a “neutral” rating in a research note on Monday, February 12th. Bank of America decreased their price objective on shares of Biogen from $280.00 to $260.00 and set a “neutral” rating for the company in a research note on Friday, April 12th. StockNews.com downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research note on Tuesday, February 20th. Finally, Wells Fargo & Company downgraded shares of Biogen from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $315.00 to $240.00 in a research note on Wednesday, February 14th. Ten equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $298.96.

Insider Buying and Selling

In related news, insider Priya Singhal sold 419 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $239.45, for a total transaction of $100,329.55. Following the sale, the insider now owns 4,516 shares in the company, valued at $1,081,356.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider Priya Singhal sold 419 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $239.45, for a total transaction of $100,329.55. Following the sale, the insider now owns 4,516 shares in the company, valued at $1,081,356.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Eric K. Rowinsky bought 455 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were purchased at an average price of $222.54 per share, for a total transaction of $101,255.70. Following the transaction, the director now owns 20,629 shares of the company’s stock, valued at approximately $4,590,777.66. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 882 shares of company stock worth $202,030. 0.60% of the stock is owned by insiders.

Biogen Stock Down 0.8 %

BIIB stock opened at $195.15 on Wednesday. The company’s 50 day simple moving average is $218.13 and its 200-day simple moving average is $236.87. The firm has a market capitalization of $28.37 billion, a PE ratio of 24.45, a P/E/G ratio of 1.87 and a beta of -0.02. Biogen Inc. has a 12 month low of $194.94 and a 12 month high of $319.76. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.00 and a quick ratio of 1.26.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 EPS for the quarter, missing the consensus estimate of $3.18 by ($0.23). The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.47 billion. Biogen had a net margin of 11.81% and a return on equity of 14.91%. During the same quarter in the prior year, the company earned $4.05 earnings per share. Equities analysts expect that Biogen Inc. will post 15.48 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.